Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor ...
Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). A phase II study with ...
This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a full text component.
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...
Introducing BCR-ABL as target for third program, in development for CML and Ph+ ALL; development candidate nomination expected by early 2024 CAMBRIDGE, Mass., Jan. 5, 2023 /PRNewswire/ -- Theseus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback